New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2013
16:06 EDTEXELExelixis announces presentation of data for its compound cabozantinib
Exelixis announced the presentation of preclinical data that provide insight into the mechanism of action of its lead compound, cabozantinib, with respect to its activity against prostate cancer tumors that have metastasized to the bone. Previously reported clinical findings with cabozantinib in castration-resistant prostate cancer patients with bone metastases have included a 67% rate of bone scan response, reduced 99Tc-MDP uptake, and reductions in plasma markers of osteoclast activity. In the poster presented today, the investigators reported on a refined prostate cancer bone metastasis model that develops many of the features associated with bone metastases in CRPC patients. "In this preclinical study, we investigated cabozantinib’s activity in an animal model of prostate cancer bone metastasis with many of the same features associated with bone metastases in CRPC patients,” said Dr. Simon Robinson, the senior author of the study. “Treatment with cabozantinib resulted in tumor cell death, increases in ADC, and normalization of bone architecture, which was accompanied by reduced uptake of 99Tc-MDP. These results suggest the compound’s effect upon bone metastases is significant and comprised of multiple mechanisms.”
News For EXEL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
09:26 EDTEXELOn The Fly: Pre-market Movers
Subscribe for More Information
06:07 EDTEXELExelixis' cobimetinib granted first regulatory approval in Switzerland
Subscribe for More Information
August 24, 2015
08:32 EDTEXELExelixis granted FDA Breakthrough Therapy Designation for cabozantinib
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use